Cystitis cost-effectiveness of therapy

Urinary Tract Infections Main Page
Cystitis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cystitis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
Echocardiography and Ultarsound
CT Scan
MRI
Other Imaging Findings
Other Diagnostic Tests
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cystitis cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cystitis cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cystitis cost-effectiveness of therapy
CDC on Cystitis cost-effectiveness of therapy
Cystitis cost-effectiveness of therapy in the news
Blogs on Cystitis cost-effectiveness of therapy
Directions to Hospitals Treating Cystitis
Risk calculators and risk factors for Cystitis cost-effectiveness of therapy

Overview

In Cystitis Disease and pathogen specific therapies are much more cost effective than broad spectrum therapies used for symptomatic treatment. Hyaluronon therapy given long term cuts down the cost of multiple pretreatments as it prevents recurrence of a Urinary tract infection.